ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1028

Association of a Non-Synonymous, Loss-of-Function, Variant in NOD2 with Reduced Tissue Damage in ACPA +Ve RA

Ricardo Segurado1, Denis Shields1, Rachel Knevel2, Annette H.M. van der Helm-van Mil3, Tom W.J. Huizinga4 and Anthony G. Wilson5, 1University College Dublin, Dublin, Ireland, 2Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 5UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Genetic Biomarkers, joint damage and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The functional capacity of individuals with rheumatoid arthritis (RA) is related to the severity of damage to bone and cartilage within joints. This is a highly variable trait that is known to have a significant genetic component. A loss-of-function non-synonymous variant (rs2066844, Arg702Trp) in nucleotide-binding oligomerization domain containing 2 (NOD2) gene, results in lower activation of NF-kB-mediated inflammation and tissue damage in RA. Our hypothesis was that the 702Trp variant is, as a result of reduced inflammatory load, be associated with lower radiological damage in RA.

Methods:

The initial study was performed in the British Genetics of RA (GORA) cross-sectional population (N=914), radiological damage was assessed by the Modified Larsen Score (MLS). Genotyping was performed using either the Illumina HumanCoreExome array (N=568) or the Illumina HumanCNV370 Quad v3 array (N=346). Genotypes for rs2066844 were imputed for individuals typed on latter platform using IMPUTE v2. Replication was performed in the Leiden EAC (N=597), with damage assessed at baseline and yearly thereafter using the Sharp-van der Heijde score (SHS) and samples were genotyped on the Illumina iScan platform (Immunochip). RF and ACPA status was available for both populations. Analyses were conducted in R v3.4.0 and SPSS v20. For the combined meta-analysis, we used the most recent measurement on each patient in a zero-inflated negative binomial model adjusted for sex and age at assessment, followed by a fixed-effects meta-analysis of the two summary statistics.

Results:

In the discovery GORA population the minor rs2066844 (702Trp) frequency was 5%, similar to the 1000 genomes European frequency (5.1%), genotypes fitted Hardy-Weinberg equilibrium. The minor allele carriage was associated with lower MLS: incidence ratio risk 0.75 (95% CI: 0.60-0.93), p=0.009. The association was only significant in RF+ (p=0.008) or ACPA+ (p=0.013) subgroups. The proportion of variance explained by rs2066844 was 0.007. In the replication Leiden cohort we observed a similar lower yearly progression of SHS score for each minor allele, by 0.95 SHS (95% CI: 0.92-0.99, p=0.006) in all patient and in ACPA positive patients (0.92, 95% CI: 0.87-0.97, p=0.004). Meta-analysis of the two cohorts revealed a significant pooled effect with an IRR of 0.76 (95% CI: 0.64-0.91 , p=0.003).

Conclusion: These data reveal a protective effect of rs2066844 minor allele with severity of sero-positive RA that is likely a consequence of the lower inflammatory activity associated with this genotype. Although the overall influence on the variance of tissue damage is modest, in combination with established prognostic biomarkers, it may contribute to the development of prognostic algorithm for RA.


Disclosure: R. Segurado, None; D. Shields, None; R. Knevel, None; A. H. M. van der Helm-van Mil, None; T. W. J. Huizinga, None; A. G. Wilson, None.

To cite this abstract in AMA style:

Segurado R, Shields D, Knevel R, van der Helm-van Mil AHM, Huizinga TWJ, Wilson AG. Association of a Non-Synonymous, Loss-of-Function, Variant in NOD2 with Reduced Tissue Damage in ACPA +Ve RA [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/association-of-a-non-synonymous-loss-of-function-variant-in-nod2-with-reduced-tissue-damage-in-acpa-ve-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-a-non-synonymous-loss-of-function-variant-in-nod2-with-reduced-tissue-damage-in-acpa-ve-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology